Research Reports | Market Assessment
April 2014

NSCLC (EGFR-Mutation-Positive; Previously Treated) | Decision Base | US/EU | 2014

Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy?

Treatment decisions for non-small-cell lung cancer (NSCLC) patients are increasingly based on personalized tumor-specific characteristics. It is now standard practice for patients with advanced NSCLC of nonsquamous-cell—particularly adenocarcinoma—histology to undergo testing for epidermal growth factor receptor (EGFR) mutations. While the first-generation EGFR tyrosine kinase inhibitors (TKIs), erlotinib (Genentech/Roche/Chugai/Astellas’s Tarceva) and gefitinib (AstraZeneca’s Iressa) have revolutionized the first-line treatment of NSCLC (EGFR-mutation-positive; previously treated), no targeted agents are currently approved in the second or subsequent- lines. Consequently, the outcome for patients with NSCLC (EGFR-mutation-positive; previously treated) remains bleak. Going forward, the market is expected to become increasingly competitive following the approval of the targeted second-generation and third-generation EGFR TKIs for NSCLC (EGFR-mutation-positive; previously treated). Despite this development, significant clinical and commercial opportunity remains for therapies that can provide greater survival benefits than current standards of care.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports